Researchers Develop Cisplatin-Resistant Bladder Cancer Cells
A new study reveals how cisplatin-resistant bladder cancer cells display increased sensitivity to enfortumab vedotin treatment.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Does research into cancer drug resistance lead to better treatment outcomes for patients?
Researchers have successfully established a cisplatin-resistant bladder cancer cell subline to better understand treatment resistance. This new subline exhibits increased sensitivity to enfortumab vedotin and monomethyl auristatin E compared to parental cells.
Why it matters
The study investigates how prior exposure to platinum-based chemotherapy impacts the effectiveness of subsequent treatments like enfortumab vedotin. This research is vital for improving patient outcomes for the 430,000 new bladder cancer cases diagnosed globally every year.
The study utilized the HT1376 bladder cancer cell line to track resistance, noting a significant upregulation of the drug efflux transporter ABCB1 in the resistant subline. Silencing this transporter successfully restored sensitivity to cisplatin.
The players
HT1376
This is the specific bladder cancer cell line used by researchers to facilitate the study of drug resistance.
The details
The cisplatin-resistant cells showed both a higher proliferation rate and increased sensitivity to enfortumab vedotin and monomethyl auristatin E. Researchers found that ABCC2 expression was also significantly increased alongside ABCB1, which previously hindered the efficacy of antibody-drug conjugates.
Timeline
February 10, 2026: Article received for publication.
October 13, 2026: Article accepted for publication.
October 29, 2026: Article published.
The Big Picture
The development of cisplatin-resistant cell lines follows the established pattern set by the development of antibody-drug conjugates for urothelial carcinoma. This study updates the understanding of resistance mechanisms previously established by the development of antibody-drug conjugates for urothelial carcinoma.
This research provides critical insight into how prior chemotherapy treatments may alter the effectiveness of subsequent therapies. These findings may eventually guide clinicians in selecting more effective treatment sequences for patients with advanced bladder cancer.
The takeaway
Understanding the specific efflux transporters involved in drug resistance can significantly improve the design of future therapies. Scientists continue to refine these findings to ensure that next-generation cancer drugs are more effective for diverse patient profiles.
Further reading
For additional context on oncological research, visit the Cancer section.
More information
Read the complete study manuscript and supporting data.
Source note: This article includes information reported by PLOS.
Live Poll
Does research into cancer drug resistance lead to better treatment outcomes for patients?
